Improved PFS and OS in HER2-Positive and Triple-Negative Breast Cancer
Four international randomised studies in early HER2-positive and metastatic triple-negative breast cancer show significant improvements in PFS, OS, and invasive disease-free survival. In this article, Hanne Melgaard Nielsen, senior consultant at the Department of Oncology, Aarhus University Hospital, Denmark, presents her perspectives on the results.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
